This article was originally published in The Gray Sheet
Medtronic plans to launch its RestoreULTRA neurostimulator for treatment of chronic back and leg pain by the end of February. The device is the smallest and thinnest 16-electrode rechargeable neurostimulator available, the company claims. It includes a remote control programmer that allows patients to make stimulation adjustments that previously could only be performed during a physician visit. FDA approved the device's PMA on Jan. 8
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.